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Radiographic progression with nonrising PSA in metastatic
castration-resistant prostate cancer: post hoc analysis of
PREVAIL
AH Bryce1, JJ Alumkal2, A Armstrong3, CS Higano4, P Iversen5, CN Sternberg6, D Rathkopf7, Y Loriot8, J de Bono9, B Tombal10,
S Abhyankar11,15, P Lin12, A Krivoshik13, D Phung14 and TM Beer2
BACKGROUND: Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA
level is the most widely used parameter for disease monitoring, but it has well-recognized limitations. Unlike in clinical trials, in
practice, clinicians may rely on PSA monitoring alone to determine disease status on therapy. This approach has not been
adequately tested.
METHODS: Chemotherapy-naive asymptomatic or mildly symptomatic men (n = 872) with metastatic castration-resistant prostate
cancer (mCRPC) who were treated with the androgen receptor inhibitor enzalutamide in the PREVAIL study were analyzed post hoc
for rising versus nonrising PSA (empirically deﬁned as 41.05 vs ⩽ 1.05 times the PSA level from 3 months earlier) at the time of
radiographic progression. Clinical characteristics and disease outcomes were compared between the rising and nonrising PSA
groups.
RESULTS: Of 265 PREVAIL patients with radiographic progression and evaluable PSA levels on the enzalutamide arm, nearly one-quarter
had a nonrising PSA. Median progression-free survival in this cohort was 8.3 months versus 11.1 months in the rising PSA cohort (hazard
ratio 1.68; 95% conﬁdence interval 1.26–2.23); overall survival was similar between the two groups, although less than half of patients in
either group were still at risk at 24 months. Baseline clinical characteristics of the two groups were similar.
CONCLUSIONS: Non-rising PSA at radiographic progression is a common phenomenon in mCRPC patients treated with
enzalutamide. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results
demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring
strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease
progression.
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INTRODUCTION
Serial PSA testing is standard practice when monitoring prostate
cancer. As a direct, downstream target gene of the androgen
receptor (AR), PSA production and secretion into the circulation
generally denotes AR-driven cellular proliferation. On the other
hand, the lack of PSA production in the setting of advanced
metastatic castration-resistant prostate cancer (mCRPC) is typically
interpreted to indicate dedifferentiation of AR-driven prostate
cancer into a more anaplastic or small-cell phenotype.1,2 These
features ﬁt into an evolving framework wherein prostate cancer is
thought to evolve from endocrine-dependent disease driven by
testis-derived androgen production, to intracrine-dependent
disease with intratumoral androgen production, to ligand-
independent but still AR-dependent disease and, ﬁnally, to
AR-independent disease.3 Whether these stages evolve over time
or co-exist early in the disease course, as suggested by recent
autopsy data,4 is not yet clear.
PREVAIL is the largest treatment study ever conducted in men
with chemotherapy-naive mCRPC. 5 PREVAIL randomized 1717
men to enzalutamide or placebo, with coprimary end points of
radiographic progression-free survival (rPFS) and overall survival
(OS). In the primary analysis, enzalutamide signiﬁcantly improved
rPFS and OS relative to placebo in men with asymptomatic or
minimally symptomatic mCRPC.5 Patients were monitored with
frequent laboratory tests, including PSA level, complete blood
count, comprehensive metabolic panel and regular imaging,
which included bone scan and computed tomography or
magnetic resonance imaging of the chest, abdomen and pelvis
every 8 weeks during the ﬁrst 6 months then every 12 weeks
thereafter.
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Conversely, in routine clinical practice, imaging is not consis-
tently obtained with the same frequency as was performed in
PREVAIL. Many practitioners rely on PSA and physical examination
as the principal measure of response and progression, and
imaging is often reserved for the evaluation of symptoms or at the
time of PSA progression. However, this practice has not been
validated and could result in delayed detection of disease
progression if disease progression occurs without a rise in PSA.
In this post hoc analysis of enzalutamide-treated PREVAIL
participants, we evaluated baseline characteristics and primary
treatment outcomes in patients with radiographic progression in
the presence or absence of a concomitant increase in PSA.
MATERIALS AND METHODS
The PREVAIL study design and methodology have been published.5 In
brief, the study enrolled men with mCRPC who were asymptomatic or
minimally symptomatic, had an Eastern Cooperative Oncology Group
Performance Status of 0 or 1 and had not received prior chemotherapy.
Patients were randomized 1:1 to receive 160 mg oral enzalutamide or
placebo once daily and continued to receive one of these treatments until
intolerance or conﬁrmed radiographic disease progression or initiation of
another therapy for prostate cancer. Patients were required to continue
androgen deprivation therapy while treated in the study.5
Assessment of PSA, ALP and LDH
Blood samples for PSA determination were collected at screening, at
baseline immediately before the ﬁrst dose of study drug, at weeks 13, 17,
21 and 25, and every 12 weeks thereafter. Serum levels of alkaline
phosphatase (ALP) and lactate dehydrogenase (LDH) were determined at
baseline, at weeks 1, 5, 13 and 25, and every 12 weeks thereafter.
Assessment of radiographic progression
Radiographic disease in soft tissue was evaluated using either computed
tomography or magnetic resonance imaging and in bone using
technetium bone scintigraphy. Imaging was performed at screening, at
weeks 9, 17 and 25, and every 12 weeks thereafter.5 Radiographic
progression was determined by independent central radiology review and
separately by investigators using Response Evaluation Criteria in Solid
Tumors version 1.1 (RECIST) for soft tissue or criteria adapted from the
Prostate Cancer Clinical Trials Working Group 2 (PCWG2) for osseous
disease.6–8 Radiographic disease progression in bone (⩾2 new lesions on
radionuclide bone scan) observed at week 9 required two additional new
lesions on a conﬁrmatory scan ⩾ 6 weeks later; radiographic disease
progression in bone observed after week 9 required persistence of two
new lesions on a conﬁrmatory scan ⩾ 6 weeks later. Radiographic disease
progression in soft tissue did not require a conﬁrmatory scan for purposes
of analysis.
Analysis populations and end points
Our post hoc analyses were conducted only in patients randomized to
enzalutamide in PREVAIL. The coprimary end points of rPFS and OS were
evaluated in two subgroups: (1) patients who met the dual conditions of
radiographic progression and a PSA level at the time of radiographic
progression that was ⩽ 1.05 times the PSA level from 3 months earlier
(‘nonrising PSA group’); and (2) patients whose PSA taken just before or at
the time of radiographic progression was 41.05 times the PSA level from
3 months earlier (‘rising PSA group’). The value of 1.05 was chosen
conservatively to limit the analysis to patients whose PSA rise was deemed
nonsigniﬁcant in clinical terms and to create clear separation from the
PCWG2 deﬁnition of PSA progression (PSA rise of 25%).
Statistical analysis
For our analyses, rPFS was deﬁned as the time from randomization to the
ﬁrst objective evidence of radiographic disease progression as assessed by
the investigator, using the same cutoff date as the OS analyses (September
16, 2013). This methodology differs from the primary analysis of rPFS in
PREVAIL, which was event-driven and based on independent central
review, using a cutoff of 6 May 2012.5 Investigator-assessed radiographic
progression was selected because of the longer follow-up period.
Analyzing the cohorts at the later cutoff allowed for a greater number of
events and was deemed to be acceptable given the 90.9% concordance
between investigator and independent review previously reported.9
For both rPFS and OS, estimates of the median and 95% conﬁdence
intervals (CIs) were determined using the Kaplan–Meier method. Hazard
ratios were determined using an unstratiﬁed Cox regression model (with
the nonrising PSA group as the only covariate) and was relative to rising
PSA, with a value less than unity favoring nonrising PSA.
We also determined the change from baseline and change at
progression from 3 months earlier in serum levels of ALP and LDH.
Code availability
Computer code used to generate the results of the time-to-event analyses
is provided in the online supplement.
RESULTS
Of 872 patients randomized to receive enzalutamide, 65 (7.5%)
had a nonrising PSA and 200 (22.9%) had a rising PSA at the time
of radiographic progression (excluding death) based on investi-
gators’ assessments as of the 16 September 2013, data cutoff. LDH
showed little change in either group, with a mean change from
3 months earlier of 4.31% (95% CI 0.48–8.15) in the rising PSA
group and − 0.6% (95% CI − 4.29–3.06) in the nonrising PSA group.
On the other hand, ALP was rising at the time of radiographic
progression in both groups; compared with 3 months earlier,
mean ALP had increased by 14.45% (95% CI 10.55–18.35) in the
rising PSA group and 4.98% (95% CI 0.72–9.24) in the nonrising
PSA group.
Median time on treatment was 8.3 months (interquartile range
(IQR) 5.6–11.2) in the nonrising PSA group and 11.1 months
(IQR 8.3–16.4) in the rising PSA group.
Baseline characteristics
Baseline patient and disease characteristics were generally similar
between the nonrising PSA and rising PSA groups with respect to
demographics and prognostic characteristics, including age,
performance status, baseline pain, baseline laboratory values,
Gleason score (median and proportion of patients with a Gleason
score ⩾ 8 at initial diagnosis) and prior therapies (Table 1).10–12 The
proportion of patients with a rising PSA at study entry was 92.3%
in the nonrising PSA group and 78.0% in the rising PSA group. The
proportion of patients with bone disease in the nonrising PSA and
rising PSA groups was similar (87.7% vs 80.5%, respectively),
although the proportion of patients with bone-only disease was
slightly lower in the nonrising PSA group (24.6% vs 30.5%). The
proportion of patients in the nonrising PSA group and rising PSA
group with soft tissue disease was 75.4% and 68.5%, respectively,
which included visceral disease (liver and/or lung, 16.9% and
10.5%) and non-liver/lung visceral metastases (primarily affecting
the renal and urologic system, 23.1% and 17.5%; represented as
other soft-tissue disease in Table 1).
As noted above, the overall rate of PSA discordance
(radiographic progression without PSA progression) was 24.5%
(65/265). By site of baseline disease, the rate of discordance
was 20.8% (16/77) in patients with bone-only disease, 34.4%
(11/32) in patients with lung or liver metastases and 30.0%
(15/50) in patients with non-liver/lung visceral metastases
(Table 1).
Clinical outcomes
Investigator-assessed median PFS was 8.3 months (95% CI 8.0–10.3)
in the nonrising PSA group and 11.1 months (95% CI 11.0–13.4) in
the rising PSA group (hazards ratio 1.68; 95% CI 1.26–2.23)
(Figure 1). There was no differential pattern of radiographic
progression in the nonrising or rising PSA groups, with a
preponderance of soft-tissue progression over bone-only
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progression (Table 2). Ninety-ﬁve patients had bone-only progres-
sion at the time of progression on enzalutamide, whereas 164
patients had soft-tissue-only progression and six had both soft-
tissue and bone progression. Notably, in patients who had bone-
only disease at study entry, 40.3% (31/77) developed soft-tissue
disease at progression.
We queried the best radiographic response in all patients with
measurable disease (46 and 106 in the nonrising PSA and rising
PSA groups, respectively). Complete or partial radiographic
responses in measurable disease occurred in 63.0% of patients
in the nonrising PSA group and 67.0% in the rising PSA group
(Supplementary Table S1). Complete response rates were lower in
the nonrising PSA group than in the rising PSA group (8.7% vs
18.9%). Although median PSA levels at the time of study entry
were higher in the nonrising PSA group than in the rising PSA
group (82.2 ng ml− 1 vs 61.3 ng ml− 1), this was not so at the time
of radiographic progression (5.5 ng ml− 1 vs 23.0 ng ml− 1). Thus,
patients with radiographic progression in the nonrising PSA group
had greater change from-baseline-to-progression reductions in
PSA levels than those in the rising PSA group (89.8% vs 50.1%;
Supplementary Table S2).
Overall survival was similar between the two groups (not yet
reached vs 32.4 months; hazards ratio 0.68; 95% CI 0.37–1.26)
(Figure 2); however, fewer than half of the patients in either
group were still at risk at 24 months. The use of subsequent
therapies with a known survival beneﬁt in prostate cancer was
Table 1. Demographics and baseline disease characteristics
Characteristic Non-rising PSA group (n= 65) Rising PSA group (n= 200)
Age, median (IQR), years 73 (68–79) 71 (65–75)
Weight, median (IQR), kg 79.1 (73.9–89.5) 84.1 (73.7–94.6)
ECOG PS, n (%)
0 46 (70.8) 143 (71.5)
1 19 (29.2) 57 (28.5)
Baseline pain score of 0–1 on BPI-SF Q3, n (%)
0–1 47 (72.3) 133 (68.2)a
⩾ 2 18 (27.7) 62 (31.8)a
Hemoglobin, median (IQR), g l− 1 131 (124–137) 129 (123–137)
Alkaline phosphatase, median (IQR), U l− 1 80 (66–114) 92 (70–141)
Lactate dehydrogenase, median (IQR), U l− 1 183 (167–203) 183 (162–215)
Albumin, median (IQR), g l− 1 39 (36–40) 38 (36–40)
PSA, median (IQR), ng ml− 1 82.2 (26.4–189.1) 61.3 (22.4–111.5)
Creatinine, median (IQR), μmol l− 1 88.4 (79–99) 85.5 (74–103)
Time from initial diagnosis to randomization, median (IQR), months 82.6 (48.1–132.2) 59.6 (33.2–112.0)
Gleason score, median (IQR) 7 (7–8) 7 (7–9)
Gleason score ⩾ 8 at initial diagnosis, n (%) 26 (41.9)b 86 (45.3)c
Type of disease progression at study entry, n (%)
PSA progression only 27 (41.5) 69 (34.5)
Radiographic progression with PSA 33 (50.8) 87 (43.5)
Radiographic progression without PSA 3 (4.6) 41 (20.5)
No disease progression per protocol 2 (3.1) 3 (1.5)
Measureable disease, n (%) 46 (70.8) 106 (53.0)
Disease localization at screening, n (%)
Bone only 16 (24.6) 61 (30.5)
Soft-tissue only 8 (12.3) 37 (18.5)
Both bone and soft tissue 41 (63.1) 100 (50.0)
None 0 2 (1.0)
Distribution of disease at screening, n (%)
Bone 57 (87.7) 161 (80.5)
Lymph node 42 (64.6) 115 (57.5)
Visceral disease (lung or liver) 11 (16.9) 21 (10.5)
Visceral liver 2 (3.1) 8 (4.0)
Visceral lung 9 (13.8) 13 (6.5)
Other soft tissue 15 (23.1) 35 (17.5)
Baseline use of corticosteroids, n (%) 2 (3.1) 8 (4.0)
Prior antiandrogen use, n (%) 57 (87.7) 176 (88.0)
Prior radiotherapy, n (%) 25 (38.5) 95 (47.5)
Prior surgery, n (%) 38 (58.5) 108 (54.0)
Prior radical prostatectomy 15 (23.1) 53 (26.5)
Abbreviations: BPI-SF Q3, Brief Pain Inventory Short Form question 3; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IQR,
interquartile range. aOne hundred and ninety-ﬁve patients were evaluable. bSixty-two patients were evaluable. cOne hundred and ninety patients were
evaluable.
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Figure 1. Kaplan–Meier estimates of progression-free survival. CI, conﬁdence interval; HR, hazard ratio; PFS, progression-free survival.
Table 2. Nature of investigator-assessed radiographic progression in the PSA concordant and discordant groups
Disease localization at screening and at progression Non-rising PSA group (n= 65) Rising PSA group (n= 200)
Bone only at screening, n (%) n = 16 n= 61
Bone-only progression 10 (62.5) 36 (59.0)
Soft-tissue disease progression 6 (37.5) 22 (36.1)
Soft-tissue and bone progression 0 3 (4.9)
Soft-tissue only at screening, n (%) n = 8 n= 37
Bone-only progression 1 (12.5) 2 (5.4)
Soft-tissue disease progression 7 (87.5) 34 (91.9)
Soft-tissue and bone progression 0 1 (2.7)
Both bone and soft tissue at screening, n (%) n = 41 n= 100
Bone-only progression 17 (41.5) 29 (29.0)
Soft-tissue disease progression 24 (58.5) 69 (69.0)
Soft-tissue and bone progression 0 2 (2.0)
None at screening, n (%) n = 0 n= 2
Soft-tissue disease progression 0 2 (100)
Figure 2. Kaplan–Meier estimates of overall survival. CI, conﬁdence interval; HR, hazard ratio; NYR, not yet reached; OS, overall survival.
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46.2% in the nonrising PSA group and 58.0% in the rising PSA
group (Table 3).
DISCUSSION
Radiographic progression with a stable or falling serum PSA level
is surprisingly common in patients treated with enzalutamide.
Although this phenomenon is recognized anecdotally, no
formal analysis has been previously reported from a prospective,
randomized trial. The nearly one-quarter of patients who
progressed on enzalutamide without any PSA progression was a
much larger proportion than expected. In fact, almost one-third of
men with visceral metastases had discordance between the PSA
and radiographic ﬁndings. It was also surprising that the median
PSA level of this population at study entry was equal to that of
patients with radiographic progression and a rising PSA. Indeed,
there were no baseline clinical characteristics that would predict
for discordance between PSA and radiographic ﬁndings. The
limited number of patients in this retrospective analysis restricts
our capacity to identify statistically signiﬁcant differences between
the groups. The slight preponderance toward baseline visceral
disease was anticipated, but the magnitude of the difference was
inadequate to vary surveillance recommendations based on
visceral disease burden.
Our results also afﬁrm the role of total ALP as a marker of
progression in patients with bone metastases. Even in the absence
of PSA progression, a rise in ALP occurred at the time of
radiographic progression. That the mean change was greater in
the rising than nonrising PSA group is likely more of a point of
interest than it is clinically important. The value of LDH appears
less clear. Although there is a modest change in LDH in the rising
PSA group, it is unchanged in the nonrising PSA group and in
general is clinically nonspeciﬁc. Given the normal ﬂuctuations in
LDH, it is hard to cite a o5% rise in LDH as an indicator of
progression.
In designing this analysis, we chose a deﬁnition of nonrising
PSA (a level at progression ⩽ 1.05 times greater than that from
3 months before radiographic progression). Although arguments
could be made for some variation of this deﬁnition, our data set
was not sufﬁciently powered to allow multiple subset analyses
using varying PSA levels. Given that PCWG2 criterion for rising PSA
is an arbitrary 25% increase over nadir, we felt it necessary to
create a wide boundary between the PCWG2 cutoff and the cutoff
for our study group to eliminate scenarios in which a PSA rise just
short of 25% was included in our study group.
The inferior PFS and OS detected in our analysis for patients
with radiographic progression and nonrising PSA levels may
signify a more aggressive clinical phenotype. The inferior PFS in
the PSA discordant groups (8.3 vs 11.1 months) was markedly
shorter than the PFS in the entire enzalutamide-treated cohort in
PREVAIL (20.0 months).9 In part this is a consequence of our
cohorts being limited to patients who developed radiographic
progression by the time of the data cutoff, thus excluding patients
who were still responding at that time. As a result, the cohorts
described herein represent early progression with or without a
rising PSA. At the time of the ﬁnal PREVAIL datalock, 61% of
enzalutamide-treated patients had not developed radiographic
progression. Similarly, the OS for the rising PSA cohort in our
analysis was only 32.4 months. In the ﬁnal PREVAIL analysis,
median OS was 35.3 months in enzalutamide-treated patients and
31.3 months in placebo-treated patients.13 That most patients in
both of our cohorts were no longer at risk for death by 24 months
means that survival estimates nearly a year later were unstable
and likely to change with longer follow-up. Indeed, the OS curves
are largely overlapping with a majority of patients at risk, and they
only separate once less than one-quarter of the patients in each
group remain. Figure 2 illustrates that the proportion of patients in
the nonrising PSA group decreases over the timeline covered in
this analysis, although it is unknown whether that trend would
continue with ongoing follow-up. It may be that the phenomenon
of nonrising PSA is most common in the ﬁrst 18 months on
enzalutamide.
The lack of PSA progression may indicate that these tumors
have become less reliant on the AR for their growth and may
indicate the need for chemotherapy or treatment using non-AR
targeting strategies. Genomic overlap between castration-resistant
tumors characterized histologically as prostate adenocarcinomas
and neuroendocrine prostate cancer has been detected by whole-
exome sequencing data of metastatic biopsies from a wide range
of anatomical sites.14 Analysis of serial biopsy samples from the
same patients revealed divergent evolution of neuroendocrine
prostate cancer from one or more prostate adenocarcinomas, an
adaptive process that promotes emergence of an alternative, ‘AR-
indifferent’ cell state as a treatment-resistance mechanism in
advanced prostate cancer.14 In addition, the West Coast Prostate
Cancer Dream Team identiﬁed a new histologic subset of mCRPC
termed ‘intermediate atypical carcinoma', which shares many
features with neuroendocrine prostate cancer and was detected in
CRPC patients exhibiting resistance to the AR-signaling inhibitors
enzalutamide and abiraterone acetate.15,16 Whether the histologic
patterns reported by those investigators are related to the clinical
picture of a stable PSA with imaging progression described in our
analysis is not known. An ongoing study of enzalutamide in the
same population as PREVAIL (patients with chemotherapy-naive
mCRPC) incorporates biopsies at baseline and progression
(NCT02099864). The histology from these biopsies should indicate
whether the intermediate atypical carcinoma phenotype is
present in those with stable PSA and progression on imaging
studies.
The role of imaging in monitoring patients with mCRPC is
another question for which these results may be impactful. Some
clinicians monitor mCRPC with PSA alone, even though a
European Consensus Panel recommended early imaging in
patients receiving AR-pathway inhibitors independently of PSA
response because of the discordance between PSA levels and
radiographic progression.17 The panel speciﬁcally cited the need
Table 3. Selected postbaseline antineoplastic therapies
Non-rising PSA group (n=65) Rising PSA group (n= 200)
Patients taking any postbaseline antineoplastic therapy, n (%) 31 (47.7) 124 (62.0)
Patients taking at least one of the following postbaseline antineoplastic therapies, n (%) 30 (46.2) 116 (58.0)
Docetaxel 24 (36.9) 94 (47.0)
Abiraterone acetate 15 (23.1) 56 (28.0)
Cabazitaxel 3 (4.6) 20 (10.0)
Sipuleucel-T 0 6 (3.0)
Enzalutamide 1 (1.5) 4 (2.0)
Progression without PSA rise
AH Bryce et al
225
Prostate Cancer and Prostatic Diseases (2017), 221 – 227
to identify early resistance and the shortcoming of PSA as a
reliable marker of progression.17 Based on our results, avoidance
of imaging might miss early disease progression. However, we do
not know if the pattern of PSA stability continues until symptoms
develop, or if the PSA eventually begins to rise as the disease
progresses.
The development of soft-tissue metastases in patients who start
therapy with bone-only disease represents another reminder that
comprehensive imaging may be necessary to fully monitor disease
status in advanced prostate cancer. Our ﬁnding that over 40% of
patients who start with bone-only disease go on to develop soft
tissue disease at progression is novel and, to our knowledge, has
not been reported before. This ﬁnding may have implications for
treatment selection and sequencing given the availability of bone
directed radiopharmaceuticals such as radium-223 dichloride.
It is difﬁcult to know if patients are harmed by delayed
detection of disease progression. Whether health-related quality
of life and pain were indicative of progression with nonrising PSA
progression was not answerable in our data set because of a lack
of data. Regardless, the utility of early detection of progression
depends on the ability to act upon that information in a way that
beneﬁts patients. As more effective treatments become available
for patients with advanced prostate cancer, it may be increasingly
important to detect treatment failure promptly so that opportu-
nities to receive life-prolonging therapy are not lost. Further, as we
gain insights into the distinct drivers of enzalutamide-resistant
mCRPC, identifying progression earlier may lead to targeted
treatments for speciﬁc emergent resistant mechanisms. In
prostate cancer, early institution of effective agents has been
well supported by the CHAARTED and STAMPEDE studies of early
docetaxel in hormone-sensitive metastatic disease.18–20 In the
randomized, double-blind ALSYMPCA study of radium-223 in
mCRPC, patients on active therapy beneﬁted from a higher quality
of life than patients receiving placebo,21 thus illustrating that
effective treatment of disease is the most effective way to prevent
the morbidity of cancer progression.
To the best of our knowledge, this paper represents the ﬁrst
systematic description of patients with nonrising PSA at radio-
graphic progression on AR-directed therapy. This population may
represent a divergent phenotype of disease requiring a different
treatment approach for patients with rising PSA, such as
chemotherapy or biopsies to better deﬁne the pathology.
Ongoing studies to deﬁne biomarkers of aggressiveness and
tumor evolution may help identify baseline characteristics of this
cohort and/or mechanistic differences underlying PSA discor-
dance with progression. Future clinical trials should report on PSA
discordant progression to better characterize this population.
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